MetLife (MET) Director Buys 7 Shares via Dividend Reinvestment at $79.29

MetLife director Christian Stephane Mumenthaler reported a small non-derivative purchase of 7 shares of MetLife, Inc. common stock on 09/09/2025 at a price of $79.29 per share.

Rhea-AI Filing Summary

MetLife director Christian Stephane Mumenthaler reported a small non-derivative purchase of 7 shares of MetLife, Inc. common stock on 09/09/2025 at a price of $79.29 per share. The filing states this purchase was an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning dividends that became payable were deferred and used to acquire additional deferred shares. After the transaction the reporting person beneficially owns 924 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/11/2025.

Insights

Financial Analyst

TL;DR: Routine dividend reinvestment yielded 7 shares, immaterial to MetLife's capital structure or valuation.

The Form 4 documents a small, non-derivative acquisition of 7 shares via dividend reinvestment for a director. At $79.29 per share this is a minor personal position change and does not alter outstanding shares or signal a change in corporate strategy. For investors, such filings typically reflect normal director compensation mechanics rather than insider accumulation or disposition. No derivative activity or planned trades are reported.

Corporate Governance Expert

TL;DR: Administrative transaction under the deferred compensation plan; procedural and compliance-oriented rather than material.

The disclosure indicates compliance with Section 16 reporting for a director whose dividends were reinvested into deferred shares. The filing follows expected governance practices: transaction code A(1) and attorney-in-fact signature show administrative handling. This is standard for non-management directors and presents no governance red flags or changes in control.

Insider Trade Summary

Grant/Award: 7 shares

Grant/Award 1 txn

Insider Mumenthaler Christian Stephane

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7	$79.29	$555.03

Holdings After Transaction: Common Stock — 924 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did MetLife director Christian Stephane Mumenthaler report on Form 4 for MET?

The director reported acquisition of 7 shares of MetLife common stock on 09/09/2025 at $79.29 per share via dividend reinvestment.

How many MetLife (MET) shares does the reporting person own after the transaction?

The filing shows the reporting person beneficially owns 924 shares following the reported transaction.

Why were the 7 MetLife shares acquired according to the Form 4?

The shares were acquired as an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors.

When was the Form 4 filed and who signed it for MET?

The Form 4 reflects the transaction date 09/09/2025 and was signed by an attorney-in-fact on behalf of the reporting person on 09/11/2025.

Does the Form 4 for MET report any derivative transactions or large changes in ownership?

No. The filing reports a small non-derivative acquisition only and no derivative securities or material ownership changes are disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mumenthaler Christian Stephane

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A(1)		7	A	$79.29	924	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.